Net Cash Provided by (Used in) Operating Activities in USD of ArriVent BioPharma, Inc. from Q1 2023 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Summary
ArriVent BioPharma, Inc. quarterly/annual Net Cash Provided by (Used in) Operating Activities history and growth rate from Q1 2023 to Q1 2025.
  • ArriVent BioPharma, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending March 31, 2025 was -$68M, a 265% decline year-over-year.
  • ArriVent BioPharma, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2024 was -$70.2M, a 25.7% decline from 2023.
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Growth (%)

ArriVent BioPharma, Inc. Quarterly Net Cash Provided by (Used in) Operating Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$68M -$49.4M -265% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-12
Q1 2024 -$18.6M -$1.75M -10.3% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-12
Q1 2023 -$16.9M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08

ArriVent BioPharma, Inc. Annual Net Cash Provided by (Used in) Operating Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$70.2M -$14.4M -25.7% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-03
2023 -$55.8M Jan 1, 2023 Dec 31, 2023 10-K 2025-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.